Panel Discussion | Is It Feasible to Conduct Meaningful Randomized Clinical Trials for Cardiogenic Shock in 2025 and Beyond?

Sunday, March 8, 2026

11:41 AM - 12:05 PM EST

Location: International Ballroom East

Moderator(s)

Jacob Eifer Møller, MD

Consultant
Rigshospitalet Copenhagen Denmark

Disclosure(s): Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)
Pooja Swamy, MD

Interventional Cardiologist
Loma Linda University Health , California, United States

Disclosure information not submitted.
Alexander G. Truesdell, MD

Interventional Cardiology
Virginia Heart / Inova Schar Heart and Vascular
McLean, Virginia, United States

Disclosure(s): Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Shockwave: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 31, 2024); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Panel Discussant(s)

Daniel Burkhoff, MD, PhD

Director: Heart Failure, Hemodynamics and MCS Research
Cardiovascular Research Foundation
New York, New York, United States

Disclosure information not submitted.
Maya Guglin, MD

Director of Heart Failure/Transplant/MCS
Indiana University
Indianapolis, Indiana, United States

Disclosure information not submitted.
Ben Kenigsberg, MD

Co-Director Medical Cardiovascular ICU
MedStar Washington Hospital Center

Disclosure(s): No financial relationships to disclose
David A. Morrow, MD

Director, Levine Cardiac Intensive Care Unit
Brigham and Women's Hospital

Disclosure(s): 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Shashank S. Sinha, MD, MSc

Director, Cardiac ICU; Director, Cardiovascular Critical Care Research
Inova Schar Heart and Vascular / Inova Fairfax Medical Campus
Fairfax, Virginia, United States

Disclosure(s): J&J Med Tech/Abiomed: Grant/Research Support (Ongoing)
Holger Thiele, MD

Head of department
Heart Center Leipzig
Leipzig, Sachsen, Germany

Disclosure(s): No financial relationships to disclose
Saraschandra Vallabhajosyula, MD MSc FACP FCCP FCCM FAHA FACC FSCAI

Assistant Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island, United States

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Jacob Eifer Møller, MD: Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)

Alexander G. Truesdell, MD: Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Shockwave: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 31, 2024); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Ben Kenigsberg, MD: No financial relationships to disclose

David A. Morrow, MD: 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Shashank S. Sinha, MD, MSc: J&J Med Tech/Abiomed: Grant/Research Support (Ongoing)

Holger Thiele, MD: No financial relationships to disclose

Saraschandra Vallabhajosyula, MD MSc FACP FCCP FCCM FAHA FACC FSCAI: No financial relationships to disclose